Authors:
E.S. Leonova1, 2, S.V. Polyakov1, 2, M.A. Pozdnyakova2, E.P. Yarygin3, S.O. Semisov2
1 nose "Road Clinical Hospital at the Gorky station OJSC" Russian Railways ", the interdorrutal center of ophthalmology, 18 Lenin Ave., Nizhny Novgorod, Russian Federation, 603140;
2GBOU VPO Nizhny Novgorod State Medical Academy, pl. Minina and Pozharsky, 10/1, Nizhny Novgorod, Russian Federation, 603950;
3GBUZ but "City Hospital No. 35", City Glack Center, ul. Osharskaya, 15, Nizhny Novgorod, Russian Federation, 603005
Place of publication:
Bulletin of ophthalmology 6, 2015
The objective is to develop an algorithm for neuroprotective treatment during the follow-up of railway workers with primary open-angle glaucoma (POAG) based on an assessment of the effectiveness of the step-by-step use of intravenous and tablet forms of the drug "Mexidol".
Material and methods. The study included patients—employees of various professions at Russian Railways—with primary open-angle glaucoma (POAG) stages I–III and compensated intraocular pressure (IOP). Mexidol was administered at a dose of 250 mg intravenously by drip for 5 days as a day patient, followed by 125 mg orally three times daily for 3 months as an outpatient. At the first, second, and third visits, patients underwent a comprehensive ophthalmological examination using high-tech monitoring techniques.
Results. Data from 58 patients (96 eyes) were analyzed. Significant improvement in perimetry and optical coherence tomography parameters was observed only at the third visit, after completion of treatment with Mexidol tablets. Patients with stages I–II of the disease showed the greatest benefit from neuroprotective therapy.
Conclusion. The results obtained during the study allow us to recommend both combination therapy with Mexidol (injectable and tablet forms) and long-term (3 months) isolated use of the tablet form for patients with primary open-angle glaucoma. Neuroprotective therapy with Mexidol is most effective in the early stages of the disease.
Key words: glaucoma, neuroprotective therapy, Mexidol, dispensary observation.
